Skip to content
★ Sign in to follow
AG

Andreas Gerward

Stayble Therapeutics ABStayble Therapeutics
Insider activity · 24 months1 buy0 salesCumulative net flow
Total declarations
10
Companies
2
▲ Purchases (3 ops.)
€13k
▼ Sales (0 ops.)
—

Latest filing published 06 Dec 2024 for Stayble Therapeutics AB, €1,636.

Filing timeline

BuySale
Andreas Gerward

Insider track record

Disclosed buys
3
Disclosed sells
0
Signal history

Closed purchases

Market purchases
3

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Andreas Gerward: trading record in brief

Andreas Gerward has filed trades across 2 companies (mainly through Finansinspektionen), most often in Stayble Therapeutics AB and Stayble Therapeutics. Between 6 March 2020 and 6 December 2024, the trades on record add up to 10 filings.

Purchases make up the whole of the open-market record (3 purchases, €13k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2024 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €4,273.

The newest entry dates from 6 December 2024: an open-market purchase of €1,636, in Stayble Therapeutics AB. Typically, a trade is published a median of 2 days after it takes place. Under the Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.

Companies and markets linked to Andreas Gerward

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations10 total
  • ▲
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    18,800 SEK23FI-SE
    40,000 shares@ SEK 0.4713.4% of flowAktieISIN SE0013513652FI:csv-ee078ff813c5631a5441
    Canonical exit: 6 Mar 2025 (T+90)
  • ▲
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    48,000 SEK26FI-SE
    160,000 shares@ SEK 0.3035.1% of flowAktieISIN SE0013513652FI:csv-02ade8dda4e159d2f0b5
    Canonical exit: 10 Sept 2024 (T+90)
  • ●
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    71,200 SEK0FI-SE
    40,000 shares@ SEK 1.7851.4% of flowBTA (betald tecknad aktie)ISIN SE0019912874FI:csv-b014ac7f2290b20f22a9
  • ●
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    0FI-SE
    28,000 shares0Teckningsrätt/UniträttISIN SE0019912866FI:csv-fecd16564f29b9e882b8
  • ●
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    0FI-SE
    250,599 shares0Teckningsrätt/UniträttISIN SE0019912866FI:csv-bf8dd7d3ab3a59aad247
  • ●
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    0FI-SE
    81,401 shares0Teckningsrätt/UniträttISIN SE0019912866FI:csv-6288494d2dbbdc02f691
  • ●
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    0FI-SE
    30,000 shares0AktieISIN SE0013513652FI:csv-4a9cedb78c3fbc59ae14
  • ▲
    Verkställande direktör (VD)ExecutivesStayble Therapeutics AB
    73,350 SEK0FI-SE
    15,000 shares@ SEK 4.89AktieISIN SE0013513652FI:csv-d3654bc9db0e699c91d6
    Canonical exit: 29 Nov 2022 (T+90)
  • ●
    VDExecutivesStayble Therapeutics
    0FI-SE
    250,000 shares0AktieISIN SE0013513652FI:csv-e56aff37dcf0c624bc28
  • ●
    VDExecutivesStayble Therapeutics
    0FI-SE
    30,000 shares0AktieISIN SE0013513652FI:csv-e69583535a22a8c42683

10 of 10 declarations